I don't think the NGIO spin-off or the 1:1 dividen

I don't think the NGIO spin-off or the 1:1 dividend can occur until the uplisting. Currently the NGIO shares are being held by the transfer agent. A value has not yet been determined.

For now our NGIO shares are privately held and cannot be publicly traded. Once the uplisting is complete and we know the value of the NGIO shares, we should be able to trade them, like any other stock. However, the NGIO shares may be IPO'd or spun off by some other process. I don't think that strategy has been made public.

Here's my preferred scenario. The AE-Kiromics merger experiences a level of success in treating cancer through immunotherapy. GNBT, which owns all of AE-Kiromics gets uplisted to NASDAQ. NGIO shares, which now have an assigned value are IPO'd. We original investors in GNBT received our shares for free in the 4:1 dividend process. Put your own figure on the IPO price. On 2/23/2019 Thomas Barnard assigned a value to the NGIO shares. I forget what it was, and the article is now available though prescription only.

However, for the sake of discussion, let's say that NGIO is valued at $5 per share, and comes public at that price. The GNBT investor received 1000 NGIO shares through the dividend process. The value of those shares is now $5000. The investor can sell them and make a quick 500% profit, he/she can sell a portion of those shares, can hold the shares to see how much new investors are willing to pay, or can hold the shares indefinitely. I believe this scenario is possible, but I'm sure someone will correct me if I'm wrong.

Hope this was helpful, OJ.